More articles from Interstitial lung disease

Effect of nintedanib on acute exacerbations of fibrosing interstitial lung diseases: a national database study in Japan
Hirokazu Urushiyama, Taisuke Jo, Wakae Hasegawa, Akira Yokoyama, Takahiro Ando, Yukiyo Sakamoto, Ryosuke Kumazawa, Kazuaki Uda, Nobuaki Michihata, Nobuyasu Awano, Matsui Hiroki, Kiyohide Fushimi, Hideo Yasunaga, Takahide Nagase

ERJ Open Research Oct 2022, 8 (4) 00209-2022; DOI: 10.1183/23120541.00209-2022
Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis
Toby M. Maher, Christina Schlecker, Doreen Luedtke, Sebastian Bossert, Donald F. Zoz, Armin Schultz

ERJ Open Research Oct 2022, 8 (4) 00240-2022; DOI: 10.1183/23120541.00240-2022
Matrix metalloproteinase-7 is increased in lung bases but not apices in idiopathic pulmonary fibrosis
Jade Jaffar, Mae Wong, Gregory A. Fishbein, Monther Alhamdoosh, Laura McMillan, Cristina Gamell-Fulla, Milica Ng, Nick Wilson, Karen Symons, Ian Glaspole, Glen Westall

ERJ Open Research Oct 2022, 8 (4) 00191-2022; DOI: 10.1183/23120541.00191-2022
Neighbourhood disadvantage impacts on pulmonary function in patients with sarcoidosis
Gillian C. Goobie, Christopher J. Ryerson, Kerri A. Johannson, Spencer Keil, Erin Schikowski, Nasreen Khalil, Veronica Marcoux, Deborah Assayag, Hélène Manganas, Jolene H. Fisher, Martin R.J. Kolb, Xiaoping Chen, Kevin F. Gibson, Daniel J. Kass, Yingze Zhang, Kathleen O. Lindell, S. Mehdi Nouraie

ERJ Open Research Oct 2022, 8 (4) 00357-2022; DOI: 10.1183/23120541.00357-2022
Analysis of real-world data and a mouse model indicates that pirfenidone causes pellagra
Koji Kuronuma, Natsumi Susai, Tomohiro Kuroita, Hiroki Yamamoto, Takeshi Yoshioka, Shuji Kaneko, Hirofumi Chiba

ERJ Open Research Oct 2022, 8 (4) 00245-2022; DOI: 10.1183/23120541.00245-2022
Functional clinical impairments and frailty in interstitial lung disease patients
Pierre-François Tremblay Labrecque, Geneviève Dion, Didier Saey

ERJ Open Research Oct 2022, 8 (4) 00144-2022; DOI: 10.1183/23120541.00144-2022
Corticosteroid-induced remission and mycophenolate maintenance therapy in granulomatous lymphocytic interstitial lung disease: long-term, longitudinal change in lung function in a single-centre cohort
Heba M. Bintalib, David M. Lowe, Gaia Mancuso, Georgia Gkrepi, Suranjith L. Seneviratne, Siobhan O. Burns, John R. Hurst

ERJ Open Research Oct 2022, 8 (4) 00024-2022; DOI: 10.1183/23120541.00024-2022
Electronically monitored medication adherence in idiopathic pulmonary fibrosis: prevalence, predictors and outcomes
Anouk Delameillieure, Wim A. Wuyts, Antoine Pironet, Fabienne Dobbels

ERJ Open Research Jul 2022, 8 (3) 00030-2022; DOI: 10.1183/23120541.00030-2022
Interstitial lung disease incidence and mortality in the UK and the European Union: an observational study, 2001–2017
Justin D. Salciccioli, Dominic C. Marshall, Richard Goodall, Conor Crowley, Joseph Shalhoub, Preya Patel, Philip L. Molyneaux

ERJ Open Research Jul 2022, 8 (3) 00058-2022; DOI: 10.1183/23120541.00058-2022
Increased monocyte level is a risk factor for radiological progression in patients with early fibrotic interstitial lung abnormality
Andrew Achaiah, Paul Lyon, Emily Fraser, Peter Saunders, Rachel Hoyles, Rachel Benamore, Ling-Pei Ho

ERJ Open Research Jul 2022, 8 (3) 00226-2022; DOI: 10.1183/23120541.00226-2022

Main menu

User menu

Search

More articles from Interstitial lung disease

Pages

Contact us